Rhythm Pharmaceuticals Stock Analysis

Rhythm Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.75. Rhythm Pharmaceuticals recorded a loss per share of 3.1. The entity had not issued any dividends in recent years. Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Rhythm Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 140 people. To find out more about Rhythm Pharmaceuticals contact the company at 857 264 4280 or learn more at https://rhythmtx.com.

Rhythm Pharmaceuticals Investment Alerts

Rhythm Largest EPS Surprises

View All Earnings Estimates

Rhythm Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Rhythm Stock Institutional Investors

Note, although Rhythm Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Rhythm Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.87 B.

Rhythm Profitablity

The company has Profit Margin (PM) of (1.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.03) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.03.

Management Efficiency

Rhythm Pharmaceuticals has return on total asset (ROA) of (0.2674) % which means that it has lost $0.2674 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8579) %, meaning that it created substantial loss on money invested by shareholders. Rhythm Pharmaceuticals' management efficiency ratios could be used to measure how well Rhythm Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of February 2026, Return On Tangible Assets is likely to drop to -0.64. In addition to that, Return On Capital Employed is likely to grow to -1.05. At this time, Rhythm Pharmaceuticals' Asset Turnover is very stable compared to the past year.

Technical Drivers

As of the 12th of February 2026, Rhythm Pharmaceuticals holds the Risk Adjusted Performance of 0.0196, semi deviation of 2.83, and Coefficient Of Variation of 6564.92. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rhythm Pharmaceuticals, as well as the relationship between them. Please check Rhythm Pharmaceuticals market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Rhythm Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 98.47 per share. Given that Rhythm Pharmaceuticals has jensen alpha of (0.05), we recommend you to check out Rhythm Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Rhythm Pharmaceuticals Price Movement Analysis

Rhythm Pharmaceuticals Insider Trading Activities

Rhythm Pharmaceuticals Outstanding Bonds

Rhythm Pharmaceuticals Predictive Daily Indicators

Rhythm Pharmaceuticals Corporate Filings

Rhythm Pharmaceuticals Forecast Models

Rhythm Pharmaceuticals' time-series forecasting models are one of many Rhythm Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Rhythm Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Rhythm Pharmaceuticals Bond Ratings

Rhythm Pharmaceuticals financial ratings play a critical role in determining how much Rhythm Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Rhythm Pharmaceuticals' borrowing costs.

Rhythm Pharmaceuticals Debt to Cash Allocation

Rhythm Pharmaceuticals currently holds 3.94 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Rhythm Pharmaceuticals has a current ratio of 5.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Rhythm Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Rhythm Pharmaceuticals Total Assets Over Time

Rhythm Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Rhythm Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Rhythm Pharmaceuticals Debt Ratio

1.0

It appears that most of the Rhythm Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Rhythm Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Rhythm Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Rhythm Pharmaceuticals Corporate Bonds Issued

Rhythm Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Rhythm Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Rhythm shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Rhythm Pharmaceuticals. By using and applying Rhythm Stock analysis, traders can create a robust methodology for identifying Rhythm entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Rhythm analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Rhythm analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Rhythm Pharmaceuticals stock analysis indicators help investors evaluate how Rhythm Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Rhythm Pharmaceuticals shares will generate the highest return on investment. By understating and applying Rhythm Pharmaceuticals stock analysis, traders can identify Rhythm Pharmaceuticals position entry and exit signals to maximize returns.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

It's important to distinguish between Rhythm Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rhythm Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Rhythm Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.